Prothena (PRTA) Competitors $14.40 +0.35 (+2.49%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PRTA vs. AKBA, URGN, PBYI, MRNS, DVAX, BHC, EWTX, MRUS, XENE, and HCMShould you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Akebia Therapeutics (AKBA), UroGen Pharma (URGN), Puma Biotechnology (PBYI), Marinus Pharmaceuticals (MRNS), Dynavax Technologies (DVAX), Bausch Health Companies (BHC), Edgewise Therapeutics (EWTX), Merus (MRUS), Xenon Pharmaceuticals (XENE), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical preparations" industry. Prothena vs. Akebia Therapeutics UroGen Pharma Puma Biotechnology Marinus Pharmaceuticals Dynavax Technologies Bausch Health Companies Edgewise Therapeutics Merus Xenon Pharmaceuticals HUTCHMED Akebia Therapeutics (NASDAQ:AKBA) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation. Which has higher earnings & valuation, AKBA or PRTA? Akebia Therapeutics has higher revenue and earnings than Prothena. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkebia Therapeutics$194.62M2.01-$51.92M-$0.23-7.78Prothena$91.37M8.48-$147.03M-$2.48-5.81 Does the MarketBeat Community prefer AKBA or PRTA? Prothena received 191 more outperform votes than Akebia Therapeutics when rated by MarketBeat users. Likewise, 70.43% of users gave Prothena an outperform vote while only 64.09% of users gave Akebia Therapeutics an outperform vote. CompanyUnderperformOutperformAkebia TherapeuticsOutperform Votes41464.09% Underperform Votes23235.91% ProthenaOutperform Votes60570.43% Underperform Votes25429.57% Do analysts prefer AKBA or PRTA? Akebia Therapeutics currently has a consensus price target of $5.75, suggesting a potential upside of 221.23%. Prothena has a consensus price target of $61.86, suggesting a potential upside of 329.56%. Given Prothena's higher possible upside, analysts clearly believe Prothena is more favorable than Akebia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Prothena 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Do institutionals and insiders believe in AKBA or PRTA? 33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 4.1% of Akebia Therapeutics shares are held by company insiders. Comparatively, 28.2% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to AKBA or PRTA? In the previous week, Prothena had 14 more articles in the media than Akebia Therapeutics. MarketBeat recorded 17 mentions for Prothena and 3 mentions for Akebia Therapeutics. Prothena's average media sentiment score of 0.41 beat Akebia Therapeutics' score of 0.15 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is AKBA or PRTA more profitable? Akebia Therapeutics has a net margin of -27.07% compared to Prothena's net margin of -98.86%. Akebia Therapeutics' return on equity of 0.00% beat Prothena's return on equity.Company Net Margins Return on Equity Return on Assets Akebia Therapeutics-27.07% N/A -20.57% Prothena -98.86%-24.19%-20.59% Which has more risk & volatility, AKBA or PRTA? Akebia Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Prothena has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. SummaryProthena beats Akebia Therapeutics on 10 of the 18 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTA vs. The Competition Export to ExcelMetricProthenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$756.01M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-5.815.5697.3414.18Price / Sales8.48348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book1.457.885.805.12Net Income-$147.03M$153.61M$119.07M$225.99M7 Day Performance-10.56%-2.00%-1.83%-1.32%1 Month Performance-12.73%-7.47%-3.64%0.60%1 Year Performance-55.43%31.80%31.62%26.23% Prothena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTAProthena1.6434 of 5 stars$14.40+2.5%$61.86+329.6%-57.8%$756.01M$91.37M-5.81173Analyst DowngradeAnalyst RevisionAKBAAkebia Therapeutics4.0169 of 5 stars$1.79-1.6%$5.75+221.2%+75.5%$390.54M$194.62M-7.78167URGNUroGen Pharma3.78 of 5 stars$11.45+2.6%$48.38+322.5%-7.9%$261.74M$82.71M0.00200PBYIPuma Biotechnology4.4141 of 5 stars$2.84+3.6%$7.00+146.5%-27.0%$134.50M$235.60M5.92185Analyst ForecastPositive NewsMRNSMarinus Pharmaceuticals4.4364 of 5 stars$0.31flat$4.79+1,448.8%-95.0%$16.97M$30.99M0.00110Analyst ForecastAnalyst RevisionDVAXDynavax Technologies4.6419 of 5 stars$12.17+1.3%$22.00+80.8%-11.0%$1.58B$260.81M93.62408BHCBausch Health Companies3.4347 of 5 stars$8.20+0.1%$7.75-5.4%+16.3%$3.01B$8.76B-17.0720,270Positive NewsEWTXEdgewise Therapeutics1.7269 of 5 stars$31.95+1.4%$38.40+20.2%+396.9%$2.98BN/A0.0060MRUSMerus1.8993 of 5 stars$42.93-1.3%$86.70+102.0%+76.7%$2.98B$43.95M0.0037Analyst ForecastXENEXenon Pharmaceuticals3.4913 of 5 stars$39.34+1.3%$57.45+46.0%+35.2%$2.96B$9.43M0.00251Analyst RevisionHCMHUTCHMED1.1549 of 5 stars$17.96+7.2%$20.55+14.4%-3.1%$2.92B$838M0.001,988Analyst DowngradeNews CoverageGap Up Related Companies and Tools Related Companies Akebia Therapeutics Competitors UroGen Pharma Competitors Puma Biotechnology Competitors Marinus Pharmaceuticals Competitors Dynavax Technologies Competitors Bausch Health Companies Competitors Edgewise Therapeutics Competitors Merus Competitors Xenon Pharmaceuticals Competitors HUTCHMED Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRTA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
